Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026
    • Home
    • Contact Us
    Penang HeraldPenang Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Penang HeraldPenang Herald
    Home » PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference
    ACCESS Newswire

    PromiCell, Inc. presents during JP Morgan’s 2026 Healthcare Conference

    January 10, 2026
    Facebook Twitter Pinterest LinkedIn Telegram Tumblr Email

    MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the “Company”), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company’s Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company’s lead asset PRO CAR – 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).

    About PromiCell, Inc.

    PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.

    Contact:

    305-433-1287
    anthony@promicell.com

    SOURCE: Promicell

    View the original press release on ACCESS Newswire

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2

    November 13, 2026

    Otunnu Campaign Releases Profile of the Candidate

    November 5, 2026

    Chervon Names Thomas Scherer Vice President of Organizational Development – Sales, End User Marketing, and Service

    November 2, 2026

    Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders

    October 30, 2026

    U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate

    October 29, 2026

    Chervon names Joel Petersheim as Vice President, End User Research and Sales – OPE Commercial USA

    October 26, 2026
    Latest News

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026
    © 2026 Penang Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.